LGND — Ligand Pharmaceuticals Incorpor
Is LGND overbought or oversold? Here is the current MarketMoodz read.
Ligand Pharmaceuticals Incorpor (LGND) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $301.71. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$301.71
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Ligand Pharmaceuticals Incorpor (LGND) exhibits a partnership/royalty business model that can generate recurring, lower‑capex revenue streams and periodic catalyst potential via partner milestones. The near‑term market environment is cautious but calm, which favors fundamentals-driven moves; however, limited fresh public filings and recent insider Form 4 activity create monitoring points. Principal upside drivers are timely partner milestone payments, licensing deals or favorable royalty trends; principal downsides are partner clinical/regulatory failures, concentrated revenue exposure, and valuation compression if expectations slip. Given mixed signals and moderate visibility, the outlook is balanced with importance placed on upcoming partner disclosures and continued monitoring of insider and EDGAR activity.
Key factors
- Business model focused on partnerships, licensing and royalties which can provide recurring, less capital‑intensive revenue streams
- Portfolio of partner programs that create cadence of milestone/royalty receipts rather than single product sales risk
- Limited public filing/data in the provided window; recent Form 4 filings indicate insider activity that merits monitoring
- Current market environment is cautious but relatively stable, reducing near‑term volatility and allowing fundamentals to dominate
- Sector dynamics: defensive flows into large‑cap pharma may not directly lift a smaller, partnership‑driven company but support overall healthcare investor interest
- Potential for partnership, licensing or milestone news to act as short‑term catalysts
Risks
- Concentration risk: revenue and growth heavily dependent on partner program success and timing of milestone/royalty payments
- Regulatory or clinical setbacks at partner companies that negatively impact royalty streams or expected milestones
- Insider Form 4 activity could signal near‑term selling pressure or governance concerns
- Valuation sensitivity: stock price may reflect expectations of continued partner success; missed expectations could lead to sharp re‑rating
- Macro and policy risk: changes in healthcare reimbursement, antitrust/regulatory actions targeting larger integrated healthcare players could create indirect headwinds
- Limited near‑term visibility due to sparse EDGAR/activity data in the provided window
See today's live rating, score and targets
Members see the live hourly rating for LGND — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.